Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

68.17
Delayed Data
As of Dec 02
 +0.42 / +0.62%
Today’s Change
67.28
Today|||52-Week Range
88.49
-20.77%
Year-to-Date
Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma with Minimal Side Effect...
Nov 30 / TheStreet.com - Paid Partner Content
Company News for November 22, 2016
Nov 22 / Zacks.com - Paid Partner Content
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
Nov 30 / Zacks.com - Paid Partner Content
Novartis Buys Selexys on Favorable Phase II Data on SelG1
Nov 22 / Zacks.com - Paid Partner Content
10 Undervalued High-Yield Dividend Stocks Worth Buying Today
Nov 30 / TheStreet.com - Paid Partner Content
Teva's Leukemia Drug Gets EU Approval in First-Line Setting
Nov 22 / Zacks.com - Paid Partner Content
Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion
Nov 30 / MotleyFool.com - Paid Partner Content
Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
Nov 21 / Zacks.com - Paid Partner Content